FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chattem Sanofi	ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020786	NDA	Chattem, Inc.	41167-4310-2	1 BLISTER PACK in 1 CARTON (41167-4310-2) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2011-03-03
Chattem Sanofi	ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020786	NDA	Chattem, Inc.	41167-4310-4	2 BLISTER PACK in 1 CARTON (41167-4310-4) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2011-03-03
Chattem Sanofi	ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION	fexofenadine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020786	NDA	Chattem, Inc.	41167-4310-6	3 BLISTER PACK in 1 CARTON (41167-4310-6) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK	2011-03-03
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis examines the global supplier landscape for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride, active pharmaceutical ingredients (APIs) central to widely used allergy and cold medications. It identifies key manufacturers, production capacities, regulatory standing, and potential supply chain vulnerabilities.

Who are the Primary Manufacturers of Fexofenadine Hydrochloride?

The production of Fexofenadine Hydrochloride is concentrated among a limited number of global API manufacturers, primarily located in Asia. These companies leverage economies of scale and established chemical synthesis pathways.

Teva Pharmaceutical Industries Ltd. (Israel): A significant player in generic API manufacturing, Teva produces Fexofenadine Hydrochloride at multiple sites, contributing to global supply.
Dr. Reddy's Laboratories Ltd. (India): This Indian pharmaceutical giant is a key supplier, with established facilities and a strong regulatory compliance record.
Sun Pharmaceutical Industries Ltd. (India): Another major Indian pharmaceutical company, Sun Pharma manufactures Fexofenadine Hydrochloride, serving both domestic and international markets.
Hetero Labs Ltd. (India): Hetero is a significant producer of various APIs, including Fexofenadine Hydrochloride, with a focus on cost-effective manufacturing.
Lupin Ltd. (India): Lupin is a diversified pharmaceutical company with a substantial API division, contributing to the Fexofenadine Hydrochloride supply.
Divi's Laboratories Ltd. (India): Known for its large-scale API production, Divi's is a notable supplier of Fexofenadine Hydrochloride.

These manufacturers are characterized by their adherence to Good Manufacturing Practices (GMP) and their ability to meet stringent quality control standards required by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What is the Production Capacity for Fexofenadine Hydrochloride?

Precise global production capacity figures for Fexofenadine Hydrochloride are proprietary. However, industry estimates suggest that the combined annual capacity of major manufacturers significantly exceeds current global demand. This overcapacity can lead to price competition among suppliers. The leading manufacturers mentioned above possess the infrastructure to scale production rapidly in response to market demand fluctuations. For instance, Teva and Dr. Reddy's have demonstrably large API production footprints, capable of producing hundreds of metric tons annually for various APIs.

Who are the Primary Manufacturers of Pseudoephedrine Hydrochloride?

The supply chain for Pseudoephedrine Hydrochloride is more complex due to regulatory controls enacted in many countries to prevent its diversion for illicit methamphetamine production. Manufacturers often operate under strict licensing and reporting requirements.

BASF SE (Germany): As a major chemical producer, BASF has been historically involved in the synthesis of precursor chemicals for Pseudoephedrine, though direct API manufacturing is more nuanced due to regulations.
Shandong Xinhua Pharmaceutical Co., Ltd. (China): A large pharmaceutical company in China, Xinhua is a significant producer of various APIs, including Pseudoephedrine Hydrochloride, operating under national regulatory frameworks.
Hubei Biocause Pharmaceutical Co., Ltd. (China): Another prominent Chinese API manufacturer, Biocause is a substantial supplier of Pseudoephedrine Hydrochloride to global markets.
Sanofi S.A. (France): While primarily a finished dosage form manufacturer, Sanofi may engage in or source Pseudoephedrine Hydrochloride API from specialized producers, adhering to strict international controls.
Mallinckrodt Pharmaceuticals (Ireland/USA): Mallinckrodt has historically been a key player in opioid and controlled substance API manufacturing, including products like Pseudoephedrine. However, the company has undergone restructuring and Chapter 11 bankruptcy proceedings, which could impact its supply chain reliability and future production.

Regulatory scrutiny impacts market entry and operational scale for Pseudoephedrine Hydrochloride manufacturers. Companies must demonstrate robust compliance with controlled substance regulations, including import/export controls and domestic distribution limits.

What are the Regulatory Considerations for Pseudoephedrine Hydrochloride?

Pseudoephedrine Hydrochloride is classified as a List I chemical by the U.S. Drug Enforcement Administration (DEA) due to its use in the clandestine synthesis of methamphetamine. This classification imposes significant restrictions on its sale and distribution.

Sales Limits: In the U.S., federal law limits the over-the-counter sale of pseudoephedrine products to 3.6 grams per day and 9 grams per 30-day period per consumer. Products containing pseudoephedrine must be kept behind the pharmacy counter [1].
Record Keeping: Retailers and distributors are required to maintain detailed records of all pseudoephedrine sales and inventory.
Import/Export Controls: International trade in Pseudoephedrine Hydrochloride is subject to stringent controls by national drug enforcement agencies and international bodies like the International Narcotics Control Board (INCB).
Manufacturing Quotas: In some jurisdictions, manufacturers may operate under production quotas set by regulatory bodies to control overall supply.

These regulations create barriers to entry and increase the operational costs for Pseudoephedrine Hydrochloride manufacturers and distributors, influencing pricing and supplier availability.

How Do Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Suppliers Differ?

The supplier landscape for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride presents distinct characteristics driven by their respective regulatory environments and market dynamics.

Feature	Fexofenadine Hydrochloride	Pseudoephedrine Hydrochloride
Regulatory Burden	Standard pharmaceutical API regulations (GMP, quality control).	Stringent controlled substance regulations (diversion prevention, sales limits, record keeping, DEA/INCB oversight).
Geographic Focus	Primarily India and Israel for API manufacturing; global distribution.	Significant production in China; more fragmented and regulated global distribution due to controls.
Number of Suppliers	Relatively larger pool of established generic API manufacturers.	Smaller, more specialized pool of manufacturers due to regulatory and security requirements.
Market Competition	High competition among generic manufacturers, driving price pressures.	Competition is tempered by regulatory barriers and the need for specialized compliance infrastructure.
Supply Chain Risk	Moderate risk, primarily related to raw material availability and geopolitical factors.	Higher risk, influenced by regulatory changes, enforcement actions, and potential diversion attempts.
R&D Investment	Focus on process optimization and cost reduction for existing generics.	Investment in secure supply chain management and compliance technologies; less on novel synthesis routes.
Pricing	Generally stable with competitive pricing; subject to raw material cost fluctuations.	Can be more volatile due to regulatory compliance costs, potential supply disruptions, and controlled distribution margins.

What are the Key Supply Chain Risks for These APIs?

Both Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride face supply chain risks, though the nature and magnitude differ.

For Fexofenadine Hydrochloride:

Raw Material Sourcing: Dependence on specific chemical precursors, which can be subject to price volatility or limited availability from upstream suppliers. Geopolitical events impacting major chemical producing regions can disrupt supply chains.
Manufacturing Disruptions: Unforeseen events at manufacturing sites, such as equipment failures, quality control issues leading to batch recalls, or natural disasters, can cause temporary shortages.
Regulatory Changes (Non-Controlled Substance): While not a controlled substance, changes in environmental regulations or labor laws in major manufacturing countries could impact production costs and availability.
Intellectual Property: While patents on the primary molecules have expired, process patents or polymorph patents can still influence manufacturing routes and market entry for some suppliers.

For Pseudoephedrine Hydrochloride:

Regulatory Enforcement and Changes: Increased scrutiny, stricter enforcement of existing regulations, or new legislative controls can significantly impact manufacturing quotas, distribution channels, and compliance costs. This is the most significant risk factor.
Diversion and Illicit Use: The constant threat of diversion for methamphetamine production can lead to supply disruptions as authorities intercept shipments or impose stricter controls on legitimate trade.
Geopolitical Instability in Manufacturing Regions: Major manufacturing hubs for Pseudoephedrine Hydrochloride are concentrated in certain regions. Political instability or trade disputes in these areas can directly affect global supply.
Limited Supplier Base: The restricted number of compliant manufacturers means that the exit or significant disruption of even one major player can have a disproportionate impact on global supply.
Logistics and Security: Enhanced security measures required for the transportation and storage of Pseudoephedrine Hydrochloride increase logistical complexity and costs.

How can Pharmaceutical Companies Mitigate Supply Chain Risks?

Pharmaceutical companies relying on Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride can implement several strategies to enhance supply chain resilience.

Supplier Diversification: For Fexofenadine Hydrochloride, engaging with multiple qualified suppliers across different geographic regions mitigates risks associated with single-source dependency. For Pseudoephedrine Hydrochloride, diversification among the limited number of compliant suppliers is critical, alongside thorough due diligence on their compliance programs.
Dual Sourcing of Key Intermediates: Identifying and qualifying alternative suppliers for critical raw materials and chemical intermediates used in the synthesis of these APIs can prevent bottlenecks.
Robust Quality Agreements and Audits: Establishing stringent quality agreements with suppliers and conducting regular, comprehensive audits ensures consistent product quality and adherence to GMP standards. This is paramount for both APIs, but especially for Pseudoephedrine Hydrochloride where compliance is complex.
Inventory Management and Buffer Stocks: Maintaining strategic inventory levels of both APIs and key raw materials can provide a buffer against short-term supply disruptions. This requires careful cost-benefit analysis, particularly for Pseudoephedrine Hydrochloride due to its controlled nature.
Supply Chain Mapping and Transparency: Gaining deep visibility into the entire supply chain, including Tier 2 and Tier 3 suppliers, allows for early identification of potential risks and vulnerabilities.
Regulatory Monitoring and Engagement: Proactively monitoring regulatory changes and engaging with regulatory bodies can help companies anticipate and adapt to new compliance requirements, particularly crucial for Pseudoephedrine Hydrochloride.
Scenario Planning and Business Continuity: Developing detailed contingency plans for various disruption scenarios (e.g., supplier failure, regulatory clampdown, natural disaster) ensures a swift and coordinated response.
Partnerships with Specialized Logistics Providers: For Pseudoephedrine Hydrochloride, partnering with logistics companies experienced in handling controlled substances ensures compliance with stringent transportation and security protocols.

Key Takeaways

Fexofenadine Hydrochloride manufacturing is dominated by a competitive landscape of Indian and Israeli API producers.
Pseudoephedrine Hydrochloride production is significantly constrained by stringent global regulations aimed at preventing diversion for illicit drug synthesis, leading to a more limited supplier base.
Supply chain risks for Fexofenadine Hydrochloride are primarily related to raw material sourcing and manufacturing disruptions.
Pseudoephedrine Hydrochloride faces higher supply chain risks due to regulatory changes, diversion potential, and geopolitical factors impacting its concentrated manufacturing regions.
Mitigation strategies include supplier diversification, robust quality management, inventory optimization, and proactive regulatory monitoring.

Frequently Asked Questions

Are there any FDA-approved domestic manufacturers of Fexofenadine Hydrochloride API in the United States? While many global pharmaceutical companies distribute Fexofenadine Hydrochloride in the U.S., the primary API manufacturing sites for this compound are predominantly located in India and Israel. U.S. regulatory approval focuses on the finished drug product's efficacy and safety, and the API’s compliance with GMP standards, rather than mandating domestic API production.
What is the current DEA quota for Pseudoephedrine Hydrochloride production in the U.S.? The DEA does not typically publish specific annual production quotas for individual List I chemicals like Pseudoephedrine Hydrochloride. Instead, it monitors the overall supply and demand and can adjust controls or investigate potential oversupply that could lead to diversion. Manufacturers and importers must apply for and obtain permits, and their activities are closely tracked.
How do regulatory changes in China impact Pseudoephedrine Hydrochloride supply globally? Given China's significant role in global API manufacturing, including Pseudoephedrine Hydrochloride, any regulatory changes there – such as increased environmental standards, stricter export controls, or enforcement of domestic drug precursor laws – can directly lead to reduced supply, increased costs, and longer lead times for international buyers.
What are the primary quality control parameters for Fexofenadine Hydrochloride API? Key quality control parameters for Fexofenadine Hydrochloride API include assay (potency), identification (e.g., via infrared spectroscopy), related substances (impurities), residual solvents, heavy metals, water content, and particle size distribution, all of which must meet pharmacopeial standards (e.g., USP, EP).
Can a company legally import Pseudoephedrine Hydrochloride into the U.S. for pharmaceutical manufacturing without significant licensing? No. Importing Pseudoephedrine Hydrochloride into the U.S. for any purpose, including pharmaceutical manufacturing, requires extensive licensing and registration with the DEA as a controlled substance importer. Companies must comply with all federal regulations, including record-keeping and reporting requirements, and may operate under specific import quotas.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Behind the Counter Medications. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/behind-counter-medications

Suppliers and packagers for generic pharmaceutical drug: FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE